Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
CJC-1295/Ipamorelin: Evidence Summary
Evidence summary for CJC-1295/Ipamorelin across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.
Back to CJC-1295/Ipamorelin overview| Indication | Evidence Tier | Trial Count | Summary |
|---|---|---|---|
| GH/IGF-1 elevation | Tier B | 3 | RCTs confirm dose-dependent GH/IGF-1 increase with individual compounds |
| Body composition improvement | Tier D | 0 | No human RCTs measuring lean mass or fat mass with this stack |
| Anti-aging outcomes | Tier D | 0 | No human data on aging biomarkers or functional outcomes |
| Exercise performance | Tier D | 0 | No human performance studies conducted |
References (3)
- Sustained GH and IGF-1 increase after single subcutaneous injection of CJC-1295 — Veldhuis JD, et al. . Journal of Clinical Endocrinology and Metabolism (2006) PMID: 16352683
- Ipamorelin, a new growth-hormone-releasing peptide: first human study — Multiple authors . Growth Hormone and IGF Research (1999) PMID: 9849822
- Pharmacokinetic-pharmacodynamic modeling of ipamorelin — Multiple authors . British Journal of Clinical Pharmacology (1999) PMID: 10496658